Study Exclusion reasons Remarks Reference(s)
Montgomery, 2021 retrospective cohort no control group

Montgomery J et al. JAMA Cardiol 10.1001/jamacardio.2021.2833

Ruddy, 2021 case series no control group

Ruddy JA AIDS 2021 Sep 1;35(11):1872-1874. 10.1097/QAD.0000000000002945

Kawasuji, 2022 - no control group

Kawasuji H et al. medrxiv;2022.02.23.22271433v1 10.1101/2022.02.23.22271433

study 101 dose finding, 2020 non randomized controlled trial no control group phase 1

Anderson EJ N Engl J Med 2020 Sep 29. 10.1056/NEJMoa2028436

Jackson LA N Engl J Med 2020 Nov 12;383(20):1920-1931. 10.1056/NEJMoa2022483

Falsey, 0 - no control group

Falsey AR et al. New England Journal of Medicine 10.1056/NEJMc2113468

BioNTech phase 2 (Walsh), 2020 randomized controlled trial no clinically relevant endpoint phase 1-2 ; dose-escalation : 13 groups of 15 participants  
Pfizer 16-25 years phase 3, 0 randomized controlled trial other very preliminary results from a press release  
Ou, 2021 case series other safety and reactogenicity, no immunogenicity

Ou MT Transplantation 2021 Apr 9. 10.1097/TP.0000000000003780

Moderna preclinical (Corbett), 2020 randomized controlled trial other

Corbett KS N Engl J Med 2020 Oct 15;383(16):1544-1555. 10.1056/NEJMoa2024671